GRAIL, Inc. (GRAL)
NASDAQ: GRAL · Real-Time Price · USD
50.26
-0.39 (-0.77%)
Apr 24, 2026, 10:03 AM EDT - Market open
GRAIL Revenue
In the year 2025, GRAIL had annual revenue of $147.17M with 17.18% growth. GRAIL had revenue of $43.60M in the quarter ending December 31, 2025, with 13.97% growth.
Revenue (ttm)
$147.17M
Revenue Growth
+17.18%
P/S Ratio
14.12
Revenue / Employee
$161,727
Employees
910
Market Cap
2.06B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 147.17M | 21.58M | 17.18% |
| Dec 31, 2024 | 125.60M | 32.49M | 34.90% |
| Dec 31, 2023 | 93.11M | 37.56M | 67.61% |
| Jan 1, 2023 | 55.55M | 40.94M | 280.17% |
| Jan 2, 2022 | 14.61M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| RadNet | 2.04B |
| Sotera Health Company | 1.16B |
| NeoGenomics | 727.33M |
| OPKO Health | 606.88M |
| Veracyte | 517.15M |
| GeneDx Holdings | 427.54M |
| Twist Bioscience | 391.56M |
| CareDx | 379.81M |
GRAL News
- 1 day ago - GRAIL to Announce First Quarter 2026 Financial Results - PRNewsWire
- 2 days ago - GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual Meeting - PRNewsWire
- 16 days ago - Grail, Epic Plan Galleri Test Integration For 450 Health Systems - Benzinga
- 16 days ago - GRAIL Announces Integration of the Galleri® Test into Epic Electronic Health Record Platform to Expand Access Nationwide - PRNewsWire
- 20 days ago - GRAL Investors Have Opportunity to Join GRAIL, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 22 days ago - Cancer Is Striking Earlier -- Superpower and GRAIL Are Partnering to Expand Early Detection - PRNewsWire
- 6 weeks ago - Grail CEO Bob Ragusa to retire, Josh Ofman named successor - Reuters
- 6 weeks ago - GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor - PRNewsWire